Core Viewpoint - Inventiva, a clinical-stage biopharmaceutical company, has announced the pricing of its public offering of 38,961,038 new American Depositary Shares (ADSs) at $3.85 per ADS, aiming to raise approximately $140.1 million in net proceeds to fund its clinical trials and working capital needs [1][8]. Offering Details - The offering price of $3.85 per ADS corresponds to €3.33 per ordinary share, reflecting a discount of 0.89% from the volume-weighted average price on Euronext [2]. - The offering is underwritten by Leerink Partners and Piper Sandler, with Namsen Capital serving as the Equity Capital Markets Advisor [3]. - The company has granted underwriters a 30-day option to purchase up to 5,844,155 additional ADSs, representing 15% of the ADSs sold in the offering [6]. Financial Proceeds and Use - The estimated net proceeds from the offering are approximately $140.1 million (€121.0 million), which could increase to $161.2 million (€139.3 million) if the underwriters' option is fully exercised [8]. - The company plans to allocate approximately 80% of the net proceeds to fund the continuation of its NATiV3 Phase 3 clinical trial and commercialization activities, while the remaining 20% will be used for working capital and general corporate purposes [9][10]. Current Financial Position - As of September 30, 2025, Inventiva had cash and cash equivalents of €97.61 million and short-term deposits of €24.71 million, which are projected to be insufficient to meet its obligations over the next 12 months without the proceeds from the offering [10][11]. Shareholder Impact - Samsara BioCapital L.P. has subscribed to 5,194,805 ADSs for approximately $19.99 million, increasing its ownership from 5.7% to 7.3% post-offering [12]. - The company's board members and executive officers are subject to a 90-day lock-up period following the offering [13]. Market Trading - The ordinary shares underlying the ADSs will be admitted to trading on Euronext under the same ISIN code as existing shares, with trading on Euronext suspended until the opening of trading on Nasdaq [29][30].

Core Viewpoint - Global Medical REIT Inc. has announced a proposed public offering of its Series B Cumulative Redeemable Preferred Stock, aiming to utilize the net proceeds for general corporate purposes, including funding new acquisitions and repaying debt [1][3]. Offering Details - The offering will include a 30-day option for underwriters to purchase additional shares to cover over-allotments [1]. - The Series B Preferred Stock is intended to be listed on the New York Stock Exchange under the ticker symbol "GMRE-PrB" [2]. - The offering is made under the company's shelf registration statement, which was declared effective by the SEC on April 4, 2024 [3]. Use of Proceeds - The net proceeds from the offering are expected to be used for general corporate purposes, which may include funding new acquisitions and repaying existing indebtedness [1]. Company Overview - Global Medical REIT Inc. operates as a net-lease medical REIT, acquiring healthcare facilities and leasing them to physician groups and healthcare systems [5].

Core Viewpoint - Inventiva plans to offer approximately $125 million (about €108 million) of new American Depositary Shares (ADSs) in an underwritten public offering in the United States, aimed at funding its clinical trials and commercialization activities [1][2]. Group 1: Offering Details - The offering will consist of new ADSs, each representing one ordinary share of the company with a nominal value of €0.01 [1]. - The net proceeds from the offering will primarily be used to fund the continuation of the NATiV3 Phase 3 clinical trial and other corporate purposes [2]. - The offering is subject to market conditions, and the final terms will be determined through a book-building process [4]. Group 2: Financial Information - As of September 30, 2025, the company had cash and cash equivalents of €97.6 million and short-term deposits of €24.7 million, which are projected to finance operations until the end of Q3 2026 [10]. - The company estimates that its current cash resources will not be sufficient to meet its obligations over the next 12 months [10]. Group 3: Regulatory and Market Considerations - The offering will be conducted without shareholders' preferential subscription rights, in accordance with resolutions from the company's general meeting [3]. - The ordinary shares represented by ADSs will be subject to an application for admission to trading on Euronext under the same ISIN code as existing shares [8]. - The trading of the company's ordinary shares on Euronext is expected to be suspended on November 13, 2025, until the opening of trading of the ADSs on Nasdaq [9]. Group 4: Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [16]. - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for MASH treatment [16].

Core Viewpoint - Vor Biopharma Inc. has announced a public offering of 10,000,000 shares at a price of $10.00 per share, aiming to raise gross proceeds of $100 million before expenses [1] Group 1: Offering Details - The offering is expected to close on or about November 12, 2025, subject to customary closing conditions [1] - Vor Biopharma has granted underwriters a 30-day option to purchase an additional 1,500,000 shares at the public offering price [1] - The shares are being offered under a shelf registration statement declared effective by the SEC on March 31, 2025 [3] Group 2: Company Overview - Vor Biopharma is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [5] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development [5]

Core Viewpoint - Plains All American Pipeline, L.P. has announced a public offering of $750 million in debt securities, which includes two types of senior notes with different maturities and interest rates [1] Group 1: Offering Details - The offering consists of $300 million of 4.70% Senior Notes due 2031 and $450 million of 5.60% Senior Unsecured Notes due 2036, priced at 99.872% and 100.518% of their face value respectively [1] - This offering is an additional issuance of previously issued notes, with $700 million of the 2031 Notes and $550 million of the 2036 Notes issued on September 8, 2025 [1] - The expected closing date for the offering is November 14, 2025, pending customary closing conditions [1] Group 2: Use of Proceeds - The net proceeds from the offering, estimated at approximately $747.2 million, will be used for general partnership purposes, including repayment of debt, intra-group lending, capital expenditures, and working capital [2] Group 3: Company Overview - Plains All American Pipeline is a publicly traded master limited partnership that operates midstream energy infrastructure and logistics services for crude oil and natural gas liquids [6] - The company manages an extensive network of pipeline systems and related infrastructure, handling over 9 million barrels per day of crude oil and NGL on average [6] - The company is headquartered in Houston, Texas [7]

Group 1 - Proactive specializes in providing fast, accessible, and actionable business and finance news content to a global investment audience [2][3] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team operates from key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2][3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - Vor Biopharma Inc. has initiated a public offering of $100 million in common stock, with an option for underwriters to purchase an additional $15 million, aimed at advancing its clinical-stage biotechnology efforts in treating autoimmune diseases [1][2]. Company Overview - Vor Biopharma is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, particularly through its lead product, telitacicept, which is in Phase 3 clinical development [5]. Offering Details - The public offering consists of $100 million in common stock, with a 30-day option for underwriters to acquire an additional $15 million [1]. - The offering is subject to market conditions and other factors, with no guarantee on completion or terms [1]. - The shares are being offered under a shelf registration statement effective since March 31, 2025, and will be made available through a prospectus supplement [3].

Core Viewpoint - Alpine Income Property Trust, Inc. has announced a public offering of 2,000,000 shares of its 8.00% Series A Cumulative Redeemable Preferred Stock at a price of $25.00 per share, expecting to raise gross proceeds of $50 million before expenses [1][2]. Group 1: Offering Details - The Series A Preferred Stock will have a liquidation preference of $25.00 per share [1]. - The offering is expected to close on November 12, 2025, subject to customary closing conditions [1]. - Underwriters have an option to purchase an additional 300,000 shares to cover over-allotments [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate and working capital purposes, which may include property acquisitions, commercial loan and investment opportunities, and repayment of debt [2]. Group 3: Listing and Management - The Company intends to file an application to list the Series A Preferred Stock on the New York Stock Exchange under the ticker symbol "PINE-PA" [2]. - Raymond James, Stifel, and Baird are acting as joint book-running managers for the offering, with several other firms as co-managers [2]. Group 4: Company Overview - Alpine Income Property Trust, Inc. is a publicly traded real estate investment trust focused on delivering attractive risk-adjusted returns and dependable cash dividends by investing in single tenant net leased commercial properties [5].

Core Viewpoint - Alpine Income Property Trust, Inc. has announced a public offering of its Series A Cumulative Redeemable Preferred Stock, with a liquidation preference of $25.00 per share, aiming to utilize the net proceeds for general corporate purposes, including property acquisitions and debt repayment [1][5]. Group 1: Offering Details - The Series A Preferred Stock will be listed on the New York Stock Exchange under the ticker symbol "PINE-PA" [2]. - The offering will be conducted under the existing shelf registration statement on Form S-3 filed with the SEC, and will be made via a prospectus supplement [3]. Group 2: Use of Proceeds - The net proceeds from the offering are expected to be used for general corporate and working capital purposes, which may include property acquisitions, commercial loan opportunities, and repayment of debt [1]. Group 3: Company Overview - Alpine Income Property Trust, Inc. is a publicly traded real estate investment trust focused on delivering attractive risk-adjusted returns and dependable cash dividends by investing in single tenant net leased commercial properties, primarily leased to high-quality publicly traded and credit-rated tenants [5].

Core Viewpoint - Guardant Health, Inc. has announced an upsized underwritten public offering of its common stock, indicating strong market interest and confidence in its growth potential [1] Group 1: Offering Details - The company is offering 3,333,333 shares of common stock at a public offering price of $90.00 per share [1] - The size of the offering was increased from a previously announced $250.0 million, reflecting a positive adjustment based on demand [1] Group 2: Market Implications - The upsizing of the offering suggests robust investor interest in Guardant Health's stock, which may enhance its capital position for future growth initiatives [1]